Espacio profesional sobre esquizofrenia, depresión y trastorno bipolar

The efficacy and safety of agomelatine, sertraline, and escitalopram for senile post-stroke depression: A randomized double-blind placebo-controlled trial.

2021
Autores 
Yao XW
Li YL
Yu ZJ
Mo CY
Pan HS
Li CY
This study aims to investigate the efficacy and safety of agomelatine, sertraline, and escitalopram for patients with senile post-stroke depression (SPSD, aged over 65 years).
Source 
National Center for Biotechnology Information (NCBI)[Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] - [cited 2021 Jun 1]. Available from: https://www.ncbi.nlm.nih.gov/